| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6068698 | The Journal of Allergy and Clinical Immunology: In Practice | 2015 | 9 Pages |
Abstract
Omalizumab 300 mg was safe and effective in reducing CIU/CSU symptoms regardless of background therapy.
Keywords
CSUIgEUASISSCIUDLQIUAS7SAEHRQOLMIDLTRAmITTLeukotriene receptor antagonistAntihistaminemodified intention-to-treatOmalizumab IgE, immunoglobulin EMinimally important differenceItchprurituschronic urticariasubcutaneousDermatology Life Quality Indexadverse eventSerious adverse eventconfidence intervalhazard ratiourticaria activity scorewhealchronic idiopathic urticariachronic spontaneous urticariaHiveUrticariaHealth-related quality of life
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Thomas B. MD, Jonathan A. MD, Marcus MD, Sarbjit S. MD, Benjamin MS, Hubert MD, Clive E. MA, MD, FRCP, Ana MD, PhD, Allen P. MD, Karin MD, PhD,